Modified Bedside Index for severity in acute pancreatitis (BISAP) score validation in the national inpatient sample database

IF 2.5 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Do Han Kim , Frank J. Lukens , Donghyun Ko , Paul T. Kröner , Miguel Salazar , Massimo Raimondo , Pedro Palacios Argueta
{"title":"Modified Bedside Index for severity in acute pancreatitis (BISAP) score validation in the national inpatient sample database","authors":"Do Han Kim ,&nbsp;Frank J. Lukens ,&nbsp;Donghyun Ko ,&nbsp;Paul T. Kröner ,&nbsp;Miguel Salazar ,&nbsp;Massimo Raimondo ,&nbsp;Pedro Palacios Argueta","doi":"10.1016/j.advms.2023.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The aim of this study was to build and validate modified score to be used in the healthcare cost and utilization project databases for further classification of acute pancreatitis (AP).</p></div><div><h3>Materials and methods</h3><p><span>The National Inpatient Sample database for the years 2016-2019 was queried for all primary adult discharge diagnoses of AP. An mBISAP score system was created utilizing the ICD-10CM codes for pleural effusion, encephalopathy, </span>acute kidney injury, systemic inflammatory response, and age &gt;60. Each was assigned a 1-point score. A multivariable regression analysis was built to test for mortality. Sensitivity and specificity analyses were performed for mortality.</p></div><div><h3>Results</h3><p>A total of 1,160,869 primary discharges for AP were identified between 2016 and 2019. The pooled mortality rate was: 0.1%, 0.5%, 2.9%, 12.7%, 30.9% and 17.8% (P ​&lt; ​0.01), respectively for scores 0 to 5. Multivariable regression analysis showed increasing odds of mortality with each one-point increment: mBISAP score of 1 (adjusted odds ratio [aOR] 6.67; 95% confidence interval [CI] 4.69-9.48), score of 2 (aOR 37.87; 95% CI 26.05- 55.03), score of 3 (aOR 189.38; 95% CI 127.47-281.38), score of 4 (aOR 535.38; 95% CI 331.74-864.02), score of 5 (aOR 184.38; 95% CI 53.91-630.60). Using a cut-off of ≥3, sensitivity and specificity analyses reported 27.0% and 97.7%, respectively, with an area under the curve (AUC) of 0.811.</p></div><div><h3>Conclusion</h3><p>In this 4-year retrospective study of a US representative database, an mBISAP score was constructed showing increasing odds of mortality with each 1-point increase and a specificity of 97.7% for a cut-off of ≥3.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"68 2","pages":"Pages 208-212"},"PeriodicalIF":2.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112623000196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

The aim of this study was to build and validate modified score to be used in the healthcare cost and utilization project databases for further classification of acute pancreatitis (AP).

Materials and methods

The National Inpatient Sample database for the years 2016-2019 was queried for all primary adult discharge diagnoses of AP. An mBISAP score system was created utilizing the ICD-10CM codes for pleural effusion, encephalopathy, acute kidney injury, systemic inflammatory response, and age >60. Each was assigned a 1-point score. A multivariable regression analysis was built to test for mortality. Sensitivity and specificity analyses were performed for mortality.

Results

A total of 1,160,869 primary discharges for AP were identified between 2016 and 2019. The pooled mortality rate was: 0.1%, 0.5%, 2.9%, 12.7%, 30.9% and 17.8% (P ​< ​0.01), respectively for scores 0 to 5. Multivariable regression analysis showed increasing odds of mortality with each one-point increment: mBISAP score of 1 (adjusted odds ratio [aOR] 6.67; 95% confidence interval [CI] 4.69-9.48), score of 2 (aOR 37.87; 95% CI 26.05- 55.03), score of 3 (aOR 189.38; 95% CI 127.47-281.38), score of 4 (aOR 535.38; 95% CI 331.74-864.02), score of 5 (aOR 184.38; 95% CI 53.91-630.60). Using a cut-off of ≥3, sensitivity and specificity analyses reported 27.0% and 97.7%, respectively, with an area under the curve (AUC) of 0.811.

Conclusion

In this 4-year retrospective study of a US representative database, an mBISAP score was constructed showing increasing odds of mortality with each 1-point increase and a specificity of 97.7% for a cut-off of ≥3.

全国住院患者样本数据库中急性胰腺炎严重程度的改良床边指数(BISAP)评分验证
目的本研究的目的是建立和验证医疗成本和利用项目数据库中用于急性胰腺炎(AP)进一步分类的修正评分。材料和方法查询2016-2019年全国住院患者样本数据库中所有成人急性胰腺炎的主要出院诊断。利用ICD-10CM代码创建mBISAP评分系统,用于胸腔积液、脑病、急性肾损伤、全身炎症反应和年龄>;60.每人得1分。建立了一个多变量回归分析来检验死亡率。对死亡率进行敏感性和特异性分析。结果2016年至2019年间,共发现1160869例AP初次出院。合并死亡率分别为:0.1%、0.5%、2.9%、12.7%、30.9%和17.8%(P​<;​0.01)。多变量回归分析显示,每增加一分,死亡率的几率就会增加:mBISAP评分为1(调整后的比值比[aOR]6.67;95%置信区间[CI]4.69-9.48),评分为2(aOR 37.87;95%CI 26.05-55.03),评分3(aOR 189.38;95%CI 127.47-81.38),评分4(aOR 535.38;95%可信区间331.74-864.02),得分为5(aOR 184.38;95%CI 53.91-63.60)。使用≥3的截止值,敏感性和特异性分析报告分别为27.0%和97.7%,曲线下面积(AUC)为0.811。结论在这项对美国代表性数据库的4年回顾性研究中,mBISAP评分显示死亡率每增加1分,其特异性为97.7%,临界值≥3。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in medical sciences
Advances in medical sciences 医学-医学:研究与实验
CiteScore
5.00
自引率
0.00%
发文量
53
审稿时长
25 days
期刊介绍: Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信